

Gary Maharaj
President and CEO

Tim Arens
Senior Vice President of Finance, IT and CFO

June 2023



Safe Harbor

Some of the statements made during this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements about predictable cash flow, accelerated revenue growth, product pipeline and catalysts in high-growth market segments, sustainable long-term growth, access to capital, opportunities to drive strong, sustained revenue growth, expected revenue growth and annual growth rates, expected contributions to fiscal 2023 revenue growth, our fiscal 2023 strategic objectives, the potential addressable markets, and market growth rates, for our products, advancing the regulatory strategy for the premarket approval of the SurVeil™ drug coated balloon (“DCB”), our expectation regarding the timing of action by the U.S. Food and Drug Administration (“FDA”) on our amended premarket approval (“PMA”) application for the SurVeil DCB, future potential revenue from our Development and Commercialization Agreement with Abbott Vascular, Inc., including a future milestone payment, expected sequential growth in the customer base for Pounce™ Thrombectomy and Sublime™ Radial Access Devices, as well as targeted year-end customers and year-over year revenue growth for such products, expectations regarding completion of the 5-year follow-up in the TRANSCEND study, fiscal 2023 financial guidance, statements about available capital, expectations about improving cash flow and our commitment to our ongoing actions to return to positive cash flow and earnings, statements about investments in long-term value creation, and estimates of future revenues related to the TRANSCEND study, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) our ability to successfully develop and commercialize our SurVeil™ DCB (including realization of the full potential benefits of our agreement with Abbott), Aves™ DCB, Sundance™ DCB and other proprietary products; (2) whether and when the FDA grants premarket approval to the SurVeil DCB (3) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies; (4) possible adverse market conditions and possible adverse impacts on our cash flows; (5) our ability to successfully and profitably commercialize the Pounce venous thrombectomy system; (6) current and future supply chain constraints; (7) whether anticipated increases in our operating expenses are effective in generating profitable revenues; (8) whether we realize the benefits of recent organizational changes without adverse impacts on our operations; and (9) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at <https://surmodics.gcs-web.com> and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Surmodics at a Glance



SURMODICS

(NASDAQ: SRDX)

We are a **Medical Technology** company focused on driving innovation to improve the prevention and detection of disease.

- Year Founded: 1979
- Locations:
 - Minneapolis, MN
 - Ballinasloe, Ireland
- Total Employees: ~402⁽¹⁾
- Fiscal 2022 Revenue: \$100 million
- Market Capitalization: ~\$320 million⁽¹⁾

⁽¹⁾As of March 31, 2023

Investment Highlights

- Core businesses operate at a significant commercial scale, generating strong, predictable cash flow
- Multiple, innovative vascular intervention devices to accelerate revenue growth profile
- Vascular intervention devices focused on large, underpenetrated markets: \$3.8B addressable opportunity⁽¹⁾
- Innovative product pipeline with catalysts in multiple high-growth market segments
- Experienced leadership team executing multi-year strategy to drive sustainable, long-term growth
- Recently enhanced balance sheet and access to capital to support strategic initiatives

⁽¹⁾ Estimated cases using relevant technology compared to total addressable cases

Patient figures and addressable market sizes are for U.S. Markets and are based on Management Estimates as well as Public Health and Industry Data.

Experienced Leadership Team



Gary R. Maharaj
President and Chief Executive Officer
(Joined 2010)




Timothy J. Arens
Senior Vice President of Finance and
Information Technology and
Chief Financial Officer
(Joined 2007)



Gordon S. Weber
Senior Vice President of Legal,
General Counsel & Secretary
(Joined 2020)



Joseph J. Stich
Senior Vice President of
Human Resources and
President of In Vitro Diagnostics
(Joined 2010)



Teryl L.W. Sides
Senior Vice President and
President of Vascular Interventions
(Joined 2018)




Charles W. Olson
Senior Vice President and
President of Medical Device
Performance Coatings
(Joined 2001)

Where we are today and where we're headed...

Core Businesses:

Medical Device Performance Coatings & In Vitro Diagnostics (IVD) Components


- Stable businesses with significant commercial scale (~\$84 million combined annual revenue in FY'22); growing modestly
- Strong gross margins
- High ROIC and cash flow generation



Growth Opportunity:

Vascular Intervention Devices

- Differentiated drug-coated balloon, thrombectomy and radial access devices
- Leverages R&D capabilities and core competency in performance coatings
- Large, underpenetrated markets
- Opportunity to drive strong, sustained revenue growth



Vascular Interventions: Product Portfolio and Pipeline

DRUG-COATED BALLOONS

For Lower-limb Interventions




SurVeil™
DRUG COATED
BALLOON

PRE-COMMERCIAL



Sundance™
DRUG-COATED BALLOON

PRE-COMMERCIAL



MECHANICAL THROMBECTOMY

For Arterial and Venous Clot Removal




Pounce™
Thrombectomy

(FOR ARTERIAL
THROMBECTOMY)



Pounce™
VENOUS
Thrombectomy

PRE-COMMERCIAL




RADIAL ACCESS PORTFOLIO

For Peripheral Interventions



Sublime™
Radial Access



Caution: Federal (US) law restricts PONCE and SUBLIME devices to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

Caution: SURVEIL, SUNDANCE Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use.

Vascular Interventions: Addressing large, underpenetrated markets in the U.S.

Product Platform	Condition(s) Addressed	Addressable Market Opportunity	Market Penetration ⁽¹⁾	Market Growth (3-Year CAGR)
	Peripheral Artery Disease Above-the-Knee	\$1.0 B	~25%	~17%
	Peripheral Arterial Occlusion	\$0.8 B	~12%	~18%
	Peripheral Artery Disease Radial Access Products	\$0.4 B	<10%	~40%
	Venous Occlusion (including those caused by Deep Vein Thrombosis)	\$1.6 B	16%	~64%
Total		\$3.8 B	~15%	~26%

Caution: Federal (US) law restricts POUNCE and SUBLIME devices to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use.

(1) Estimated cases using relevant technology compared to total addressable cases
Addressable market opportunity and market growth are for U.S. Markets and are based on Management Estimates as well as Public Health and Industry Data.

Fiscal 2023 Strategic Objectives

1 >



SurVeil™ Drug-Coated Balloon

Advance regulatory strategy with the goal of achieving FDA Pre-Market Approval (PMA)

2 >



Pounce™
Thrombectomy



Sublime™
Radial Access

Pounce™ Thrombectomy (Arterial) and Sublime™ Radial Access platforms

Develop direct sales force and advance commercialization of platform products

3 >




Medical Device Performance Coatings and In Vitro Diagnostics offerings

Drive revenue and cash flow growth

Caution: Federal (US) law restricts POUNCE and SUBLIME devices to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use.



SurVeil™ DCB: Product Overview

Overview


- Designed to treat peripheral artery disease in the vessels above the knee using a proprietary drug-excipient formulation to reduce the likelihood of restenosis

Advantages

- Designed to deliver similar therapeutic outcomes to other DCB's, with a lower drug dose
- Better efficiency of drug transfer
- Reduction in downstream embolization

Clinical Evidence

- TRANSCEND pivotal trial (446 patients, 65 global sites): primary safety and efficacy endpoints met
- Two-year data showed a primary patency rate of 70.8% of subjects for SurVeil™ DCB subjects, vs. 70.4% for IN.Pact® Admiral® DCB (control arm) subjects



Check here for
product specs and
TRANSCEND trial
24-month data




SurVeil™ DCB: Market Opportunity & Commercial Strategy

Peripheral Artery Disease Above-the-knee Annual, Addressable U.S. Market⁽¹⁾

~500,000

Annual, Addressable
Above-the-knee Procedures




~120,000

Annual Above-the-Knee
DCB Procedures

Commercial Strategy & Strategic Objectives

- Development & Distribution Partnership secured with Abbott
 - Upon FDA Pre-Market Approval (PMA), Surmodics will manufacture and sell SurVeil™ DCB to Abbott
 - Abbott's salesforce will commercialize SurVeil™ DCB and share profits with Surmodics
- FY'23 objective:
 - Advance regulatory strategy, with the goal of achieving PMA

(1) Patient figures and market penetration based on Management Estimates, iData Research reports as well as Public Health and Industry Data
(2) Total DCB cases as a percent of total procedures




Caution: Federal (US) law restricts this device to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

© 2023 Surmodics, Inc. All rights reserved.



Pounce™ Thrombectomy System (Arterial): Product Overview



Overview

- Designed to capture and remove clots from occluded arteries in the peripheral vasculature

Advantages

- Designed to provide efficient and effective clot removal, restoring blood flow quickly without the need for capital equipment or lytic drugs ⁽¹⁾, lessening the potential for an ICU stay
- Intuitive, simple set up; limited learning curve
- Unique design makes it easy to remove large quantities of organized (hard) or fresh (soft) thrombus through a low profile, 7-French sheath


(1) FIM data Charing Cross Symposium: 100% procedure success; 95% of cases did not require thrombolytics; successfully covered wide range of clot and organized debris - Surmodics data on file.

Pounce™ Thrombectomy System (Arterial): Market Opportunity & Commercial Strategy

Arterial Clot Removal Annual, Addressable U.S. Market

185,000

Peripheral Arterial
Occlusion Patients



23,000

Patients treated with arterial
clot removal procedure

Commercial Strategy & Strategic Objectives

Commercializing Pounce™ Thrombectomy System in the U.S.
via direct sales force:

- FY'22 achievements:
 - Hired and onboarded direct sales force
 - Scaled commercialization to include all U.S. territories
 - Launched improved device handle
 - Advanced new product pipeline with Pounce™ LP and XL thrombectomy programs
- FY'23 objectives:
 - Advance commercialization efforts and marketing programs
 - Initiate Pounce™ LP Limited Market Evaluation (LME)
 - Initiate Pounce™ PROWL registry


(1) Patient figures and market penetration based on Management Estimates as well as Public Health and Industry Data

(2) Total mechanical thrombectomy cases as a percent of total procedures

Caution: Federal (US) law restricts this device to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.



Sublime™
Radial Access



120 cm Guide Sheath
5 Fr, 6 Fr

150 cm Guide Sheath
5 Fr, 6 Fr

From wrist to foot, through
the pedal loop and **UP** the
contralateral tibial artery

250 cm .014" RX PTA

200 cm Microcatheter
.014", .018", .035"

220 cm .018" RX PTA


Sublime™
Guide Sheath




Sublime™
Microcatheter



Sublime **014**
RX PTA



Sublime **018**
RX PTA



Sublime™ Radial Access: Platform Overview

Radial Access is the new frontier in peripheral interventions, with significant benefits, compared with standard transfemoral access, for patients and practitioners alike

✓ Reduced complications

50–80% relative risk reduction in access site complication^{1,2}

✓ Reduced bleeding

47% reduction in major bleeding and a 77% reduction in complications^{1,3}

✓ Rapid recovery

Quick ambulation and early discharge frees up staff, beds and resources to increase volume^{1,4}

✓ Positive patient experience

Patients experienced less pain and greater walking ability post-procedure^{1,5}

Overview

- Designed to treat stenosed arteries from the thigh to the foot via radial (wrist) access point

Advantages

- **Sublime™ Radial Access** products provide a unique combination of length, profile and deliverability relative to competitive products, allowing physicians to access lesions previously inaccessible from radial access
- **Sublime™ Radial Access Guide Sheath**
 - Kink resistance – 60% better kink resistance¹
 - Radial Strength – 15% stronger¹
 - Torque Transmission – 1.3X better torque response¹ resulting in better support and pushability through tough lesions
 - Thin-walled design allows physicians to leverage radial access with more patients
- **Sublime™ RX PTA Dilatation Catheters**
 - Crossability¹ and pushability¹ exceed other PTA balloons
 - Our 250 cm 014” Sublime™ RX PTA catheter is 25% longer than any other commercial 014” PTA balloon

¹Based on average measurements from bench testing by Surmodics, Inc. Data on file.

1. As compared to transfemoral access in coronary procedures

2. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet* 2011;377:1409-20.

3. Ferrante G, et al. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients with Coronary Artery Disease. A Meta-Analysis of Randomized Trials. *JACC: Cardiovascular Interv.* Vol 9(14), 25 July 2016:1419-1434.

4. Lindner SM, McNeely CA, Amin AP. The Value of Transradial: Impact on Patient Satisfaction and Health Care Economics. *Interv Cardiol Clin.* 2020 Jan;9(1):107-115.

5. Cooper C, El-Shiekh R, Cohen D, et al. Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison. *Am Heart J.* 2010; 138(3), 430-436.

The Sublime™ Radial Access Platform

FROM WRIST TO FOOT. CONFIDENTLY.

Access

Sublime™ Guide Sheath

Industry's first radial length 5 Fr sheath, available in 5 Fr and 6 Fr, 120 cm and 150 cm.



Cross

Sublime™ Microcatheter

High-performance peripheral crossing catheter available in .014", .018", and .035" diameters and lengths of 65 cm – 200 cm.



Treat

Sublime™ RX PTA Dilatation Catheters

Industry's longest working length PTA catheters available in up to 250 cm.




Sublime™ Radial Access: Market Opportunity & Commercial Strategy

Radial Access Annual Addressable U.S. Market⁽¹⁾

840,000

Patients treated with
ATK or BTK Interventions



~75,000

Patients treated with radial
access interventions

Commercial Strategy & Strategic Objectives

Commercializing Sublime™ Radial Access Platform products in the U.S.
via direct sales force:

- FY'22 achievements:
 - Hired and onboarded direct sales force
 - Scaled commercialization to include all U.S. territories
 - Drove clinical and market awareness through the execution of radial peer-to-peer training courses
- FY'23 objective:
 - Advance commercialization efforts and marketing programs
 - Achieve FDA 510(k) clearance for Sublime™ Microcatheter and initiate Limited Market Evaluation (LME)

(1) Patient figures and market penetration based on Management Estimates, iData Research reports as well as Public Health and Industry Data

(2) Estimated market size if all patients were treated with available Sublime™ devices

(3) Total radial access cases as a percent of total procedures

Caution: Federal (US) law restricts this device to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.




Financial Summary

Significant Commercial Scale with Multiple Catalysts for Future Growth

- 5-year CAGR of 6.5% through FY'22
- FY'23 Revenue growth to benefit from:
 - Contributions from initial commercialization of key, approved products (Pounce™ System and Sublime™ Platform)
 - Single-digit revenue growth in our Medical Device Performance Coatings and In Vitro Diagnostics offerings
- FY'23 SurVeil license fee revenue from Abbott expected to range from ~\$4.0-\$4.5M, vs. \$5.7M in FY'22

Annual Revenue - Millions



⁽¹⁾ Midpoint of guidance ranging from \$103 - \$106 million

FY'23 Financial Guidance Overview

Total Revenue: \$103 to \$106 million, up 3% to 6% year-over-year

GAAP Diluted Loss per Share⁽¹⁾: \$(2.30) to \$(2.00), compared to \$(1.96) in FY'22

Non-GAAP Diluted Loss per Share⁽²⁾: \$(1.98) to \$(1.68), compared to \$(0.95) in FY'22

- GAAP and Non-GAAP diluted loss per share reflect continued investment in our Pounce™ thrombectomy and Sublime™ radial access products, as well as the impact of the spending reduction plan initiated in the second quarter of our FY'23
- As has been the company's practice with past guidance, revenue from regulatory-related milestones, such as upon receipt of PMA for the SurVeil™ DCB, is not included in guidance until after they are achieved

⁽¹⁾ GAAP earnings per share is the estimated fiscal 2023 diluted earnings per share as determined by U.S. generally accepted accounting principles.

⁽²⁾ Non-GAAP earnings per share adjusts GAAP earnings per share for estimated fiscal 2023 acquired intangible amortization totaling \$0.23 per share (\$0.28 in fiscal 2022), net of tax as well as fiscal 2023 restructuring expenses totaling \$0.09 per share, net of tax. In fiscal 2022, Non-GAAP earnings per share included an adjustment to exclude tax expense for a full valuation allowance against U.S. deferred tax assets totaling \$0.73 per share.

Available Capital & Capital Allocation Priorities

Focused on maintaining liquidity, ensuring access to capital and enhancing cash management...

Available Capital (\$M) ⁽¹⁾

Cash	\$19.1
Revolving Line-of-Credit ⁽²⁾	\$11.1
Term Loan ⁽²⁾	\$50.0
Total Available Capital	\$80.2

...while positioning Surmodics to generate strong, sustainable growth and enhance future value

Invest in Long-term Value Creation

Support the Core Medical Device Performance Coatings & IVD Businesses

- Optimize revenue and cash flow performance

Drive Growth of Key New Products

- Support Abbott's U.S. commercialization of SurVeil™ DCB upon FDA Approval
- Advance the initial U.S. commercialization Pounce™ System & Sublime™ Platform products

Invest in Innovation

- Drug-coated balloons
- Thrombectomy platform
- Radial access platform

(1) As of March 31, 2023

(2) Our five-year credit agreement with MidCap Financial consists of up to \$100 million in term loan financing (\$25 million at MidCap's discretion) and a \$25 million revolving credit facility, availability of which is based upon eligible inventory and receivables)



Key Developments & Related Expectations

Substantial Progress Toward Attainment of the SurVeil PMA Approval



SurVeil™
DRUG COATED
BALLOON

Recently, we filed our amended PMA application with the FDA after numerous productive interactions with the Agency


- Since receipt of the January non-approval letter from the FDA, we have made significant progress towards obtaining PMA approval:
 - ✓ Multiple discussions with the FDA Management resulting in alignment on process to address the Agency's concerns related to already-completed biocompatibility studies and revisions to our proposed labeling
 - ✓ Based on the interactive discussions with the FDA, we have submitted our amended SurVeil PMA Application in May – with no new testing required
 - ✓ Ongoing interactive review of the amended application has progressed as expected with constructive alignment on all issues
- SurVeil PMA decision expected in Q4 FY'23

Our Market Development of Pounce™ Thrombectomy and Sublime™ Radial Access is Gaining Traction

Pounce™ Thrombectomy (Arterial) and Sublime™ Radial Access platforms together are becoming a growth catalyst

- The customer base has been and is expected to continue to grow sequentially
- We expect continued account growth to drive strong revenue growth, benefiting from a growing pipeline of prospective customers
- Product sales growth is contributing significantly to Surmodics' overall revenue growth

Pounce Thrombectomy and Sublime Platforms Customer Accounts



We are targeting to finish FY'23 with:

>200 Customers and ≈ 300% Year-Over-Year Revenue Growth

We are Focused on Improving Cash Flow

Cash flow improvement to come from multiple sources

- We recently implemented a spending reduction plan and communicated expectations to reduce our quarterly cash use to approximately \$3.5-\$4.0 million beginning Q3 FY'23
- We remain committed to our ongoing actions to reduce our use of cash and return to positive cash flow and earnings by:
 - Disciplined ongoing expense management, including our recent spending reduction measures
 - Growth in total revenue and gross profit, driven by strong contributions from sales of our Pounce™ thrombectomy and Sublime™ radial access products

Summary: Significant Upside Potential

- Surmodics' experienced leadership team is executing a multi-year strategy to drive sustainable, long-term profitable growth
- Our core businesses continue to operate at a significant commercial scale, generating strong, predictable cash flow
- The successful commercial launch and early market development of multiple, innovative vascular intervention devices, each focused on large, underpenetrated markets, has begun to impact our revenue growth significantly in FY'23
- Our innovative product pipeline, including our SurVeil™ DCB, and important additions to our Pounce™ Thrombectomy and Sublime™ Radial Access platforms are promising catalysts in multiple, high-growth market segments
- We have recently enhanced our balance sheet and access to capital to support our strategic initiatives, while also reducing spending and prioritizing investment in our key strategic growth initiatives

Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use.

Caution: Federal (US) law restricts POUNCE and SUBLIME devices to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.



SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE, AVESSE, TELEMAR, SERENE and the SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE and AVESSE logos are trademarks of Surmodics Inc. and/or its affiliates. All third-party trademarks are trademarks of their respective owners. All rights reserved.



Appendix

Strategic Agreement with Abbott



Abbott



February 27, 2018 – Abbott and Surmodics Announced Agreement for Next-Generation Drug-Coated Balloon Development and Commercialization

- Exclusive worldwide commercialization rights for SurVeil™ drug-coated balloon (DCB) for superficial femoral artery (SFA)
- We have received \$60.8 million in total milestones from Abbott
- Final milestone of \$27 million (\$24 million if achieved after June 30, 2023) due upon receipt of PMA approval from the FDA provided Abbott chooses to commercialize the product and does not exercise their right to terminate the agreement if PMA approval is obtained after December 31, 2023
- Revenue to be realized from product sales to Abbott, including a base transfer price plus a share of profits from Abbott sales of the device

Surveil™ DCB: Impact to Financials

\$61M of the potential \$88M of SurVeil™ DCB upfront and potential milestone **payments** have been achieved through Q2 FY2023

Payment	Amount	Date
Upfront License Fee	\$25M	Feb 2018
TRANSCEND Enrollment Milestone	\$10M	Aug 2019
CE Mark Milestone	\$10.8M	June 2020
Clinical Report Milestone	\$15M	Feb 2021

~90% of the estimated total \$35M – \$40M TRANSCEND Clinical Study costs were incurred through Q2 2023

Upfront and milestone revenue is recognized based upon the % of the TRANSCEND study costs incurred⁽¹⁾

TRANSCEND Study Cost Schedule⁽¹⁾


	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Value Creating Event	Abbott Agreement Signed	TRANSCEND Enrollment Complete	CE Mark Received	Final Clinical Report Delivered				5-year Follow-Up Complete
Estimated % of TRANSCEND Study Costs Incurred⁽¹⁾	~18%	~51%	~65%	~76%	~85%	~92%	~97%	~100%

SurVeil™ Milestone Revenue Recognition Schedule


Revenue (\$ in millions)	FY 2021A	FY 2022A	FY 2023E
Upfront License Fee	\$2.6	\$2.3	\$1.6 - 1.8
TRANSCEND Completion Milestone	1.0	0.9	0.7 - 0.8
CE Mark Milestone	1.1	1.1	0.7 - 0.8
Clinical Report Milestone	11.3	1.0	1.0 - 1.1
PMA Approval Milestone	-	-	-
Total SurVeil Upfront & Milestone Revenue	\$16.0	\$5.7	\$4.0 – 4.5
Cumulative Revenue	\$45.9	\$51.6	\$55.6 - \$56.1
% recognized ⁽¹⁾	~76%	~85%	~92%

(1) TRANSCEND costs incurred following the execution of the SurVeil™ DCB development and distribution agreement with Abbott Vascular and not the actual cost from study inception


We expect to recognize the entire \$60.8 million associated with the license fee and achieved milestones over the period ending fiscal 2025; revenue from the up-to \$27 million of outstanding milestones (if any) will be recognized over the same time period, beginning in the period of achievement



Pounce Venous Thrombectomy: Product Overview



The basket is expanded to maintain vessel wall contact.
(vessel range 6 - 16 mm)



The extraction screw is activated and removes clot at the point of collection.



The basket dynamically adjusts to vessel anatomy, controlled by a constant-tension spring located in the handle.

Check out
the full
animation



Overview

- Designed to separate, macerate and remove clots from occluded veins in the peripheral vasculature

Advantages

- Shorter device profile, compared to competitive mechanical devices, simplifies the procedure
- Lower profile, 10 French design reduces potential for access site complications
- Uniquely designed to limit the number of passes required to remove the clot, resulting in lower procedure time and fewer potential complications
- No use of lytic drugs required in most cases⁽¹⁾


(1) No thrombolytics used in 84.2% of cases in a 19-patient clinical study.

Pounce™ Venous Thrombectomy: Market Opportunity & Commercial Strategy

Venous clot removal, including Deep
Vein Thrombosis (DVT)⁽¹⁾ Annual,
Addressable U.S. Market

270,000

Addressable
Procedures⁽¹⁾



\$1.6B

16% Current
Penetration⁽²⁾

44,000

Patients treated with
mechanical thrombectomy

Commercial Strategy & Strategic Objectives

Commercializing Pounce™ Thrombectomy System and the Sublime™ Radial Access Platform products in the U.S. via direct sales force:

- Commercializing Sublime & Pounce products in the U.S. via direct sales force
 - FY'22 objectives:
 - Completed manufacturing validations
 - FY'23 objective:
 - Conduct Pounce™ Venous Thrombectomy System clinical product evaluations

(1) Our devices have not received DVT disease state clinical indication clearance at this time. Patient figures based on Management Estimates as well as Public Health and Industry Data

(2) Total mechanical-only clot removal cases as a percent of total procedures

Sundance™ Sirolimus-coated Balloon: Product Overview

1

Uniform sirolimus drug coating

Sirolimus + Proprietary Excipient
360° uniform coating coverage

2


Surmodics .014" PTA platform

2 – 4 mm diameter
20 – 220 mm lengths

3

Hydrophilic shaft coating

Surmodics Serene™
hydrophilic coating



Overview

- Designed to treat peripheral artery disease in the vessels below the knee using a proprietary drug-excipient formulation to reduce the likelihood of restenosis

Advantages⁽¹⁾

- Excellent drug coating durability
- Higher levels of drug transfer and unique ability to achieve sustained therapeutic levels in tissue
- Robust, lasting biological effect

Clinical Evidence

- SWING first-in-human (FIH) study results presented at the 2022 Amputation Prevention Symposium in Lugano, Switzerland by Dr. Ramon Varcoe
- FIH data demonstrating an excellent safety profile and the lowest binary restenosis at six months (36%), compared to relevant below-the-knee trials


(1) Based on average measurements from bench and preclinical testing sponsored by Surmodics, Inc. Data on file.

Medical Device Performance Coatings

Performance COATINGS



HYDROPHILIC



HEMOCOMPATIBLE



DRUG-DELIVERY

The Magic Is In The Coating

Estimated Distribution of Surmodics' Royalty Revenues


ROYALTY REVENUE DISTRIBUTION^{1,2}

<10%

25%-35%

Structural Heart

Royalty Rev = <10%
CAGR = 12-15%



Neurological

Royalty Rev = 25-35%
CAGR = 5-9%

Cardiovascular

Royalty Rev = 25-35%
CAGR = (1)-2%

Peripheral Vascular

Royalty Rev = 25-35%
CAGR = 4-6%

Surmodics' performance coatings are critical to the successful delivery of medical devices used in complex procedures where maneuverability and control are essential



Hydrophilic

Low friction and low particulates to improve deliverability



Hemocompatible

Active and passive coatings; customizable to blood compatibility and durability requirements



Drug-Delivery

Durable and biodegradable coatings using proprietary polymers to control delivery rates and mechanical properties


1. Based upon Surmodics' historical royalty revenue mix
2. CAGRs = Needham & Associates and Company estimates

A Stable Foundation For Future Growth

Medical Device Performance Coatings

- Over 150 license agreements among 100 customers
- 34 U.S. patents issued; 79 International patents Issued
- Royalty rates for new licenses typically range from 2-3% for the device application
- Product gross margins on the high end of medical device industry averages
- Our Medical Device Performance Coatings revenue is expected grow in the low-to-mid-single digits, annually


ANNUAL COATINGS REVENUE
(MILLIONS)



Growth: (10)% 10% 2%


(1) Impacted by COVID-19 as well as patent expiration for our 4th generation coating

REVENUE BREAKDOWN



■ Royalties & License Fees
■ Product
■ Research & Development

In Vitro Diagnostics (IVD)



AMP UP THE SIGNAL.
DIAL DOWN THE NOISE.

Leading Provider of Components for In Vitro Diagnostic (IVD) Tests



Protein stabilizers,
diluents & blockers



ELISA
substrates



Microarray
slides & surfaces



Antigens & antibodies
from DIARECT™ part
of BBI solutions™



Stop solutions &
support reagents


In Vitro Diagnostics

- Our components are used in test kits sold by the majority of the top ten global in vitro diagnostics companies
- > 1000 unique customers in several categories: Kit manufacturers, R&D institutions, Distributors and OEM's
- Point of care testing and regulatory changes are disrupting the market and represent opportunity for market share growth

Continued Outstanding Results

IN VITRO DIAGNOSTICS

REVENUE (MILLIONS)



- Our IVD business is expected to continue to deliver low-to-mid-single digit revenue growth annually
- Strong and growing customer base with broad portfolio of differentiated products
- Strong operating margin of approximately 47% of revenue, or \$13.1 million in FY2022
- The ~\$28B global immunoassay market is expected to grow ~2%, annually⁽¹⁾

1.Global market based on management estimates as well as industry data

Clinical Advisors



Gary Ansel, MD, FACC
Clinical Advisor — Interventional
 Cardiology
 Healthcare Insights



Stephen Black, MD
Clinical Advisor — Vascular Surgeon
 St. Thomas Hospital



Marianne Brodmann MD, PhD
Clinical Advisor — Interventional Cardiology
 Division of Angiology Medical University Graz



William Gray, MD
Clinical Advisor — System Chief,
 Division of Cardiovascular Disease
 Main Line Health



CLINICAL ADVISORS



Raghu Kolluri, MD, MS, RVT
Clinical Advisor — Vascular Medicine &
 Vascular Labs
 Ohio Health Heart and Vascular Service



Michael Lichtenberg,
Clinical Advisor — Interventional
 Angiologist
 Klinikum Hochsauerland



Constantino Peña, MD
Clinical Advisor — Vascular and
 Interventional Radiology
 Miami Cardiac & Vascular Institute



Ken Rosenfield, MD
Chair Advisory Board —
 Interventional Cardiology
 Massachusetts General Hospital



Peter Schneider, MD
Clinical Advisor — Vascular Surgery
 University California San Francisco



Prof. Ramon Varcoe
Clinical Advisor — Vascular Surgeon
 Prince of Wales Hospital



Renu Virmani, MD, FACC
Clinical Advisor — Cardiovascular
 Pathologist
 CVPPath